Feasibility of Novel Slim Peroral Cholangiopancreatoscopy for the Diagnosis of Pancreatobiliary Disease
DEN Open · 2026-04 · 6 (1)
DOI: 10.1002/deo2.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift DEN Open, online erschienen am 02.06.2025. Verfasst von Haruo Miwa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterological Center Yokohama City University Medical Center Yokohama Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the clinical outcomes of peroral cholangiopancreatoscopy (POCPS) using the 9‐Fr eyeMAX for the diagnosis of pancreatobiliary diseases.
Methods
This retrospective study enrolled 43 patients who underwent POCPS using the 9‐Fr eyeMAX for diagnostic procedures at two tertiary referral centers between May 2023 and November 2024. The primary outcome was the incidence of adverse events following POCPS. Patient backgrounds, procedural details, technical success (successful insertion of the 9‐Fr eyeMAX), and adequate tissue sampling were also analyzed.
Results
Of the 43 patients, 32 were male, and 11 were female, with a median age of 75 years (range, 46–87 years). Peroral cholangioscopy (POCS) was performed on 30 patients. The final diagnosis in this cohort was an ampullary tumor ( n = 2), extrahepatic bile duct cancer ( n = 16), gallbladder cancer ( n = 3), metastatic liver tumor ( n = 1), and benign biliary stricture ( n = 8). The adequate tissue sampling rate for the POCS was 86.4%. Adverse events after POCS occurred in two patients (6.7%), including mild pancreatitis ( n = 1) and fever ( n = 1). Peroral pancreatoscopy (POPS) was performed on 13 patients. The final diagnoses of all patients undergoing POPS were intraductal papillary mucinous neoplasms (IPMN), categorized as branch duct‐type IPMN ( n = 1), mixed‐type IPMN ( n = 8), and main duct‐type IPMN ( n = 4). The technical success rate was 92.3% (12/13). The tissue sampling rate for POPS was 83.6%. No adverse events, such as pancreatitis, were observed.
Conclusions
The 9‐Fr eyeMAX facilitates a safe POCPS procedure, achieving a high technical success rate and an adequate tissue sampling rate.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterological Center Yokohama City University Medical Center Yokohama Japan.
- Department of Gastroenterology Yokohama City University Hospital Yokohama Japan.
- Department of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.
ORCID-Profile: Haruo Miwa, Yoshihiro Goda, Yuichi Suzuki
Zitieren
APA
Miwa, H., Sugimori, K., Irie, K., Goda, Y., Shibasaki, K., Ishino, Y., Tsunoda, S., Endo, K., Oishi, R., Suzuki, Y., Tsuchiya, H., Funaoka, A., Anan, H., Suzuki, Y., Kaneko, T., Morimoto, M., Numata, K., & Maeda, S. (2026). Feasibility of Novel Slim Peroral Cholangiopancreatoscopy for the Diagnosis of Pancreatobiliary Disease. DEN Open, 6(1). https://doi.org/10.1002/deo2.70152
Vancouver
Miwa H, Sugimori K, Irie K, Goda Y, Shibasaki K, Ishino Y, et al. Feasibility of Novel Slim Peroral Cholangiopancreatoscopy for the Diagnosis of Pancreatobiliary Disease. DEN Open. 2026;6(1). doi:10.1002/deo2.70152
BibTeX
@article{Miwa2026,
author = {Miwa, Haruo and Sugimori, Kazuya and Irie, Kuniyasu and Goda, Yoshihiro and Shibasaki, Kozue and Ishino, Yugo and Tsunoda, Shotaro and Endo, Kazuki and Oishi, Ritsuko and Suzuki, Yuichi and Tsuchiya, Hiromi and Funaoka, Akihiro and Anan, Hideyuki and Suzuki, Yoshimasa and Kaneko, Takashi and Morimoto, Manabu and Numata, Kazushi and Maeda, Shin},
title = {Feasibility of Novel Slim Peroral Cholangiopancreatoscopy for the Diagnosis of Pancreatobiliary Disease},
journal = {DEN Open},
year = {2026},
volume = {6},
number = {1},
doi = {10.1002/deo2.70152}
}
EUVIMED